Filing Flows › Enovis (ENOV) › Q2 2026 › vs Q2 2025
Enovis (ENOV) Q2 2026 vs Q2 2025 (year over year)
Enovis's revenue rose $18.2M (+3%) from $565M in Q2 2025 to $583M in Q2 2026. The biggest changes: Reconstructive +$20.6M (+8%); Prevention & Recovery −$2.3M (-0.8%).
Enovis, Q2 2026: revenue $583M (+3% year over year), operating margin 3.0%, net loss $1.0M, operating cash flow $75.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.3% | 0.6% | +4.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Reconstructive | $295M | $274M | $20.6M | +8% |
| Prevention & Recovery | $288M | $291M | −$2.3M | -0.8% |
| Revenue | $583M | $565M | $18.2M | +3% |
| Net loss | $1.0M | $36.5M | −$35.5M | -97% |
| Costs & expenses | $584M | $601M | −$17.3M | -3% |
| Operating costs | $565M | $581M | −$16.0M | -3% |
| Interest & other, net | $9.9M | $8.9M | $1.1M | +12% |
| Income tax | $8.5M | $10.8M | −$2.3M | -21% |
| Cost of revenue | $224M | $230M | −$6.3M | -3% |
| Research & development | $31.7M | $30.7M | $986K | +3% |
| SG&A | $264M | $267M | −$3.3M | -1% |
| Other operating costs | $46.4M | $53.7M | −$7.3M | -14% |
| Operating cash sources | $80.0M | $80.2M | −$225K | -0.3% |
| Depreciation & amortization | $71.0M | $71.6M | −$525K | -0.7% |
| Share-based compensation | $9.0M | $8.7M | $300K | +3% |
| Net loss absorbed | $1.0M | $36.5M | −$35.5M | -97% |
| Working capital & other | $3.9M | −$4.1M | $8.0M | — |
| Operating cash flow | $75.0M | $47.8M | $27.3M | +57% |
| Free cash flow (OCF − capex) | $31.1M | $3.4M | $27.7M | +816% |
| Capital expenditures | $43.9M | $44.4M | −$474K | -1% |
Questions
How much did Enovis's revenue grow year over year in Q2 2026?
Enovis's revenue rose $18.2M (+3%) from $565M in Q2 2025 to $583M in Q2 2026.
What drove Enovis's revenue change in Q2 2026?
Reconstructive +$20.6M (+8%); Prevention & Recovery −$2.3M (-0.8%).